Does Rallies show Form 4 insider transactions for AXSM?

Yes. Rallies tracks AXSM insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is AXSM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AXSM. It does not provide personalized investment advice.

AXSM (Axsome Therapeutics, Inc) Stock Analysis - Insider Trades

Axsome Therapeutics, Inc (AXSM) is a publicly traded Healthcare sector company. As of May 21, 2026, AXSM trades at $231.00 with a market cap of $11.70B and a P/E ratio of -61.59. AXSM moved +1.82% today. Year to date, AXSM is +34.48%; over the trailing twelve months it is +112.85%. Its 52-week range spans $75.56 to $235.92. Analyst consensus is strong buy with an average price target of $261.88. Rallies surfaces AXSM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading AXSM stock inside the company?

Recent AXSM insider activity includes Jacobson Mark L. sold 233, Jacobson Mark L. sold 4.52K, Maizel Ari sold 7.50K, Coleman Mark sold 25.00K, and Jacobson Mark L. sold 35.38K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

AXSM Key Metrics

Key financial metrics for AXSM
Metric	Value
Price	$231.00
Market Cap	$11.70B
P/E Ratio	-61.59
EPS	$-3.72
Dividend Yield	0.00%
52-Week High	$235.92
52-Week Low	$75.56
Volume	7
Avg Volume	0
Revenue (TTM)	$708.24M
Net Income	$-188.30M
Gross Margin	0.00%

Recent AXSM Insider Trades

Jacobson Mark L. sold 233 (~$53.17K) on May 5, 2026.
Jacobson Mark L. sold 4.52K (~$1.03M) on May 4, 2026.
Maizel Ari sold 7.50K (~$1.37M) on Apr 22, 2026.
Coleman Mark sold 25.00K (~$4.03M) on Feb 26, 2026.
Jacobson Mark L. sold 35.38K (~$5.73M) on Feb 26, 2026.

Latest AXSM News

Axsome jumps as Q1 sales surge 57% and AUVELITY Alzheimer’s approval boosts outlook — May 5, 2026
Guggenheim Lifts Axsome Therapeutics Price Target to $260 After 57% Q1 Revenue Surge — May 4, 2026
Axsome jumps as Q1 revenue surges 57% and Alzheimer’s launch plans firm up — May 4, 2026
Axsome’s Q1 Revenue Soars 57% to $191.2M, FDA Approves Auvelity — May 4, 2026
Axsome slides as traders lock in gains after FDA win, ahead of May 4 earnings — May 1, 2026

AXSM Analyst Consensus

19 analysts cover AXSM: 0 strong buy, 18 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $261.88.

Common questions about AXSM

Who is trading AXSM stock inside the company?: Recent AXSM insider activity includes Jacobson Mark L. sold 233, Jacobson Mark L. sold 4.52K, Maizel Ari sold 7.50K, Coleman Mark sold 25.00K, and Jacobson Mark L. sold 35.38K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for AXSM?: Yes. Rallies tracks AXSM insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is AXSM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AXSM. It does not provide personalized investment advice.